New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
07:40 EDTRPTPRaptor receives cysteamine bitartrate orphan drug designation from EC
Raptor Pharmaceutical announced that the European Commission approved its application for orphan drug designation of cysteamine bitartrate, the active ingredient in RP103, for the treatment of Huntington's disease. The decision follows a positive recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency in June. In February of this year, Raptor announced "encouraging top line" results from a planned 18-month analysis of the blinded, randomized, placebo-controlled phase of its ongoing CYST-HD clinical trial of RP103 in patients with early-stage Huntington's disease. Raptor submitted the 18-month CYST-HD results as part of the orphan application.
News For RPTP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RPTP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use